Please select the option that best describes you:
In cases in which Oncotype DX test is not available, how do you decide which patients with HR+ and Her2- breast cancer are candidates for adjuvant chemotherapy?
How would your management differ in pre- and post-menopausal females?
Answer from: Medical Oncologist at Academic Institution
If OncotypeDx is not available for an ER+ Her2- primary breast cancer:
In general, there are two main components to the 21 gene assay: proliferative thrust and estrogenic signaling. Thus tumors that have strong staining for ER tend to be driven by estrogenic signaling. This is especially true...
Sign in or Register to read more